262 related articles for article (PubMed ID: 25802230)
1. The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.
Tsai KK; Daud AI
Drugs; 2015 Apr; 75(6):563-75. PubMed ID: 25802230
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-1 therapy in melanoma.
Homet Moreno B; Parisi G; Robert L; Ribas A
Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
6. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
9. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
11. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Kwak G; Kim D; Nam GH; Wang SY; Kim IS; Kim SH; Kwon IC; Yeo Y
ACS Nano; 2017 Oct; 11(10):10135-10146. PubMed ID: 28985469
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
13. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now.
Juárez-Salcedo LM; Sandoval-Sus J; Sokol L; Chavez JC; Dalia S
Crit Rev Oncol Hematol; 2017 May; 113():52-62. PubMed ID: 28427522
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade: a common denominator approach to cancer therapy.
Topalian SL; Drake CG; Pardoll DM
Cancer Cell; 2015 Apr; 27(4):450-61. PubMed ID: 25858804
[TBL] [Abstract][Full Text] [Related]
17. Immune modulation in cancer with antibodies.
Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
[TBL] [Abstract][Full Text] [Related]
18. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
20. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.
Dolan DE; Gupta S
Cancer Control; 2014 Jul; 21(3):231-7. PubMed ID: 24955707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]